Prenetics Global Ltd (PRE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, insider confidence, and recent share buyback plan suggest significant long-term potential. Despite some technical indicators showing neutral or slightly bearish trends, the overall sentiment and fundamentals support a buy decision.
The MACD histogram is negative (-0.521) but contracting, suggesting a potential reversal. RSI is neutral at 27.773, and moving averages are converging, indicating no strong trend. Key support is at 14.864, and resistance is at 18.463. The stock is trading near resistance levels, but pre-market momentum (+10.02%) indicates bullish sentiment.

$40 million share buyback plan to address stock undervaluation.
Insider confidence with $1.3 million stock purchases, including $750,000 by the CEO.
Revenue guidance for IM8 brand at $180-$200 million for 2026, showcasing strong growth potential.
Significant YoY revenue growth of 248.57% in Q4 2025.
Net income remains negative at -$28.12 million, though improving YoY.
EPS is still negative (-1.75), which may deter some investors.
Neutral sentiment from hedge funds and insiders over the last quarter.
In Q4 2025, revenue increased by 248.57% YoY to $36.56 million. Net income improved by 72.05% YoY but remains negative at -$28.12 million. EPS increased by 36.72% YoY to -1.75, and gross margin improved significantly by 34.49% to 59.47%. These figures indicate strong growth trends despite ongoing losses.
Roth Capital initiated coverage with a Buy rating and a $36 price target, citing IM8's rapid scaling to over $100 million in revenue and its underappreciated growth potential at current share levels.